human glucagon peptide online manufacturer Manufacturer

Glucagon (human),CAS#: 16941-32-5, Molecular Weight:3482.8 A 29 amino acid sequence containing peptide hormone processed from proglucagon that keeps glucose homeostasis in vivo in both animals and humans. It is also believed to be a potential tool in the therapeutic treatment of diabetes. Technical Data for Glucagon (Human, Porcine) M. Wt 3482.78 Formula C153H225N43O49S Sequence HSQGTFTSDYSKYLDSRRAQDFVQWLMNT Storage Store at -20C Purity 95% (HPLC) CAS Number 16941-32-5

GLP-2 (1-34) (human),CAS#: 99120-49-7, Catalog Number: KS032009 Glucagon-like peptide-2 (GLP-2) promotes nutrient absorption via expansion of the mucosal epithelium by stimulation of crypt cell proliferation and inhibition of apoptosis in the small intestine. It also reduces epithelial permeability, and decreases meal-stimulated gastric acid secretion and gastrointestinal motility. GLP-2 promotes the expansion of the intestinal epithelium through stimulation of the GLP-2

GLP-2 (1-33) (human),CAS#: 223460-79-5, Catalog Number: KS032008 This is a fragment of human intestinal growth factor glucagon-like peptide 2, GLP2, containing amino acids 146 to 178. It is an intestinotrophic growth hormone that promotes many aspects of intestinal function, including enhancement of mucosal growth and promotion of nutrient absorption. GLP-2 is a hormone that can rapidly improve intestinal epithelial barrier function. Technical Data for GLP-2 (human) M. Wt

GLP-2 (1-34) (human),Catalog Number: KS061029,CAS NO.: 99120-49-7 GLP-2 (Glucagon-like peptide-2) induces the expansion of the mucosal epithelium in the small intestine by stimulating crypt cell proliferation while inhibiting apoptosis. This expansion leads to an increase in nutrient absorption while simultaneously reducing epithelial permeability and decreasing meal-stimulated gastric acid secretion and gastrointestinal motility. GLP-2 achieves these effects by activating

GLP-2 (1-33) (human),Catalog Number: KS032008,CAS NO.: 223460-79-5 This is a fragment of human intestinal growth factor glucagon-like peptide 2, GLP2, containing amino acids 146 to 178. It is an intestinotrophic growth hormone that promotes many aspects of intestinal function, including enhancement of mucosal growth and promotion of nutrient absorption. GLP-2 is a hormone that can rapidly improve intestinal epithelial barrier function.

Amylin (rat),CAS#: 124447-81-0, Catalog Number: KS032012 Rat/mouse Amylin differs from the human version in 6 amino acids: H18R, F23L, A25P, I26V, S28P and S29P (first letter is the amino acid of the human sequence). Unlike the human IAPP (Amylin), rat Amylin does not form amyloid fibers. Technical Data for Amylin (rat) M. Wt 3920.43 Formula C167H272N52O53S2 Sequence (Modifications: Tyr-37 = C-terminal amide, Disulfide bridge between 2 - 7) Storage Store at -20C CAS Number

GLP-1 (1-36) amide (human),CAS#: 99658-04-5, Catalog Number: KS032010 In response to Glucose ingestion, proglucagon in the intestinal L cells is cleaved into GLP-1 (1-36). Prior to secretion into the circulation, GLP-1 (1-36) is further processed into amidated GLP-1 (7-36) and small amounts of glycine-extended GLP-1 (7-37). Both GLP-1 (7-36) and GLP-1 (7-37), causes glucose dependent release of insulin by pancreatic beta-cells. They also play a role in gastric motility

GxTx-1E,Catalog Number: K1110-V,Store at -20C or -80C,Lyophilized Guangxitoxin 1E is a Kv2.1 and Kv2.2 channel blocker (IC50 values are 1-3 nM). Enhances glucose-stimulated insulin secretion from human islets in vitro, but not from islet cells lacking the Kv2.1 channel. Has no significant effect on plasma insulin, glucagon or blood glucose levels in mice, but increases plasma somatostatin levels. Main Sales Markets: North America,Central/South America,Western Europe,Eastern

Sermaglutide CAS 910463-68-2 Molecular Weight 4113.64 On September 20, 2019, the FDA officially approved the marketing application for Sommarutide, which is used in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes. Sommarutide is a human GLP-1 analogue with high albumin affinity and a long half-life. It can be administered once a week to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner.

A 29 amino acid sequence containing peptide hormone processed from proglucagon that keeps glucose homeostasis in vivo in both animals and humans. It is also believed to be a potential tool in the therapeutic treatment of diabetes.